SGLT-2 inhibition has been demonstrated to reduce the risk of heart failure hospitalisation in people with stable established symptomatic heart failure with reduced ejection fraction (HFrEF) by the DAPA-HF and EMPEROR-REDUCED trials, with relative effects similar in people with and without DM [11, 13]. The gene discussed is SLC5A2; the disease is heart failure.